Home Other Building Blocks Pregna-1,4-diene-3,20-dione, 16,17-[[(R)-cyclohexylmethylene]bis(oxy)]-11,21-dihydroxy-, (11β,16α)-

Pregna-1,4-diene-3,20-dione, 16,17-[[(R)-cyclohexylmethylene]bis(oxy)]-11,21-dihydroxy-, (11β,16α)-

CAS No.:
161115-59-9
Catalog Number:
AG001S60
Molecular Formula:
C28H38O6
Molecular Weight:
470.5977
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%
1 week
United States
$251
- +
10mg
99%
1 week
United States
$321
- +
25mg
99%
1 week
United States
$598
- +
Product Description
Catalog Number:
AG001S60
Chemical Name:
Pregna-1,4-diene-3,20-dione, 16,17-[[(R)-cyclohexylmethylene]bis(oxy)]-11,21-dihydroxy-, (11β,16α)-
CAS Number:
161115-59-9
Molecular Formula:
C28H38O6
Molecular Weight:
470.5977
MDL Number:
MFCD09027385
IUPAC Name:
(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
InChI:
InChI=1S/C28H38O6/c1-26-11-10-18(30)12-17(26)8-9-19-20-13-23-28(22(32)15-29,27(20,2)14-21(31)24(19)26)34-25(33-23)16-6-4-3-5-7-16/h10-12,16,19-21,23-25,29,31H,3-9,13-15H2,1-2H3/t19-,20-,21-,23+,24+,25+,26-,27-,28+/m0/s1
InChI Key:
OXPLANUPKBHPMS-ZXBNPROVSA-N
SMILES:
OCC(=O)[C@@]12O[C@@H](O[C@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@H]2[C@H]1CCC1=CC(=O)C=C[C@]21C)C1CCCCC1
EC Number:
605-247-3
UNII:
8DL7FH77SF
Properties
Complexity:
949  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
9  
Defined Bond Stereocenter Count:
0
Exact Mass:
470.267g/mol
Formal Charge:
0
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
470.606g/mol
Monoisotopic Mass:
470.267g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
93.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.7  
Literature
Title Journal
Formoterol synergy with des-ciclesonide inhibits IL-4 expression in IgE/antigen-induced mast cells by inhibiting JNK activation. European journal of pharmacology 20150815
Ciclesonide--a novel corticosteroid for the management of asthma. Current clinical pharmacology 20120501
Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway. Pulmonary pharmacology & therapeutics 20111201
Simultaneous determination of ciclesonide and its active metabolite desisobutyryl-ciclesonide in human plasma by LC-APCI-MS/MS: application to pharmacokinetic study in healthy Chinese volunteers. Journal of pharmaceutical and biomedical analysis 20110428
Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. Journal of clinical pharmacology 20101001
Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers. Clinical therapeutics 20091201
Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide. Clinical pharmacokinetics 20090101
Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide. Clinical pharmacokinetics 20080101
Modulation of human lung fibroblast functions by ciclesonide: evidence for its conversion into the active metabolite desisobutyryl-ciclesonide. Immunology letters 20070915
The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochemical pharmacology 20070515
In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharmaceutics & drug disposition 20070101
Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa. BMC pharmacology 20070101
In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharmaceutics & drug disposition 20060501
Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. Journal of clinical pharmacology 20060401
High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respiratory medicine 20060301
Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. European journal of pharmacology 20060215
Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. International journal of clinical pharmacology and therapeutics 20060101
Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog. American journal of therapeutics 20060101
Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. The Journal of pharmacology and experimental therapeutics 20050801
Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. European journal of clinical pharmacology 20050501
Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. Journal of clinical pharmacology 20050201
Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. American journal of therapeutics 20050101
Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. American journal of therapeutics 20050101
Ciclesonide. Drugs 20040101
Properties